← Leaderboards
Eric Hermann Decloedt
Stellenbosch University
$303,371
Attributed
$606,742
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $165.9K · FY2021–24$200K$150K$100K$50K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$606,742 · 2
By mechanism
R21$606,742 · 2
Top collaborators
- Catherine Orrell2 shared
- Giovanni Schifitto2 shared
Others in their field
Other Emerging Leaders on “Participant”
- Chanza Baytop · Westat, Inc.$271,217,917
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$102,389,765
- Scott Topper · Broad Institute, Inc.$101,052,360
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
Research focus
ParticipantPharmaceutical PreparationsInflammationSouth AfricaStandard Of CarePlasmaCardiovascular Risk FactorIncomeRegimenPrevalenceAfrica South Of The SaharaSouth AfricanAnti-Retroviral AgentsBlood VesselsBiological MarkersAntiretroviral TherapyCountryFutureInflammatoryPersonsBaseBasal GangliaAutomobile DrivingArterial Tonometry
Grant awards (4)
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke$138,481
R21 · FY2024 · TW · contact PI
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke$165,925
R21 · FY2023 · TW · contact PI
Study of Metformin to reduce Cerebrovascular Dysfunction in South African patients with HIV and Metabolic Syndrome: A Phase II Pilot Trial. SMART$145,800
R21 · FY2022 · TW · contact PI
Study of Metformin to reduce Cerebrovascular Dysfunction in South African patients with HIV and Metabolic Syndrome: A Phase II Pilot Trial. SMART$156,536
R21 · FY2021 · TW · contact PI